Miriam Pérez-Almarcha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Miriam Pérez-Almarcha has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Ana Galvez-Llompart
Department of Psychiatry, Clinical Hospital of Valencia, Valencia, Spain
1 shared publication - Isabel Ballester-Gracia
Department of Psychiatry, Clinical Hospital of Valencia, Valencia, Spain
1 shared publication - Miguel Hernandez-Viadel
Psychiatry Department, University Clinic Hospital, Valencia, Spain
1 shared publication
Latest Publications
- Open Access
- 28 August 2019
- Published by Springer Nature in BMC Pharmacology and Toxicology
- Vol. 20 (1) , 1-4
Use of long acting injectable aripiprazole before and through pregnancy in bipolar disorder: a case report
Long-acting injectable (LAI) antipsychotics for psychotic disorders provide advantages in treatment compliance, but data on their use in pregnancy are very limited. We present a clinical case of aripiprazole LAI use in pregnancy. A 43-year-old woman diagnosed with bipolar disorder, with several relapses due to treatment interruption while trying to conceive. Finally, aripiprazole LAI treatment was planned by mutual agreement between doctor and the patient, who took aripiprazole LAI before and during pregnancy. She gave birth at 40 weeks to a 3500 g baby girl with no congenital malformations, who was healthy at 5 months after delivery. As far as we know, this is the first case report on aripiprazole LAI use during pregnancy. Although we exercise caution in drawing conclusions from a single case, and each case should be weighed up individually, aripiprazole LAI could be a therapeutic option in similar circumstances.
- 28 August 2019
- Published by Springer Nature in BMC Pharmacology and Toxicology
- Vol. 20 (1) , 1-4
Open AccessUse of long acting injectable aripiprazole before and through pregnancy in bipolar disorder: a case report
Long-acting injectable (LAI) antipsychotics for psychotic disorders provide advantages in treatment compliance, but data on their use in pregnancy are very limited. We present a clinical case of aripiprazole LAI use in pregnancy. A 43-year-old woman diagnosed with bipolar disorder, with several relapses due to treatment interruption while trying to conceive. Finally, aripiprazole LAI treatment was planned by mutual agreement between doctor and the patient, who took aripiprazole LAI before and during pregnancy. She gave birth at 40 weeks to a 3500 g baby girl with no congenital malformations, who was healthy at 5 months after delivery. As far as we know, this is the first case report on aripiprazole LAI use during pregnancy. Although we exercise caution in drawing conclusions from a single case, and each case should be weighed up individually, aripiprazole LAI could be a therapeutic option in similar circumstances.